Quantcast
Last updated on April 16, 2014 at 21:24 EDT

Latest Partial seizure Stories

2012-01-31 11:41:00

After surgical success, patient gives back through raising awareness and money for epilepsy CHICAGO, Jan. 31, 2012 /PRNewswire-USNewswire/ -- When reflecting back on the most significant day in their life, most people think of their wedding anniversary, or a birthday. For Howard Zwirn, however, January 16, 2004, is a much more important milestone - it's the day the seizures he had experienced for seven years stopped. "That day changed my life and my family's life," said Zwirn....

2011-03-29 11:15:00

LONDON and MISSISSAUGA, Ontario, March 29, 2011 /PRNewswire/ -- GlaxoSmithKline (GSK) and Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced today that the European Commission has granted marketing authorisation for Trobalt(TM) (retigabine) as an adjunctive (add-on) treatment of partial onset seizures (a form of epilepsy where a seizure begins in a specific area in one side of the brain), with or without secondary generalisation in adults aged 18 years and above...

2010-12-07 13:01:49

Mayo Clinic researchers studied more than 200 children with epilepsy and found that even if the cause of focal-onset seizures cannot be identified and they do not fit into a known epilepsy syndrome, long-term prognosis is still excellent. This study was presented at the American Epilepsy Society's (http://www.aesnet.org/) annual meeting in San Antonio on Dec. 4. Epilepsy (http://www.mayoclinic.org/epilepsy/) is a disorder characterized by the occurrence of two or more seizures. It affects...

2010-10-01 14:25:38

More than 50 percent reduction in partial seizure frequency; safety, efficacy confirmed Researchers from the Arkansas Epilepsy Program found treatment with rufinamide results in a significant reduction in seizure frequency compared with placebo, for patients with uncontrolled partial-onset seizures (POS). Details of this study are now available online in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy. Epilepsy affects up to 2% of the...

2010-04-09 08:16:00

ATLANTA, April 9 /PRNewswire/ -- The antiepileptic drug (AED) Vimpat® (lacosamide) (C-V) will be the subject of numerous studies and analyses at the 62nd annual American Academy of Neurology (AAN) meeting, taking place at the Metro Toronto Convention Centre in Toronto from April 10-17. To view the multimedia assets associated with this release, please click: http://www.prnewswire.com/mnr/vimpat/34012/ "The breadth and depth of Vimpat data being presented at AAN...

2009-08-23 13:05:15

Study identifies pathway that helps control brain synapses A form of partial epilepsy associated with auditory and other sensory hallucinations has been linked to the disruption of brain development during early childhood, according to a study led by researchers at Beth Israel Deaconess Medical Center (BIDMC). Described in today's Advance On-line issue of Nature Medicine, these new findings provide the first genetic link between childhood brain development and a seizure disorder that lasts...

2009-06-29 00:00:00

S. MAMEDE DO CORONADO, Portugal, June 29 /PRNewswire/ -- Data presented today, in Budapest, demonstrated that add-on treatment with the novel, once-daily anti-epileptic Zebinix(R)* (eslicarbazepine acetate; ESL) resulted in a marked and sustained decrease in seizure frequency over the long-term(1). Results from the one-year extension of a pivotal Eslicarbazepine Acetate phase III study were presented at the International Congress for Epilepsy in Budapest, Hungary. Patients not...

2009-04-28 00:00:00

S.MAMEDE DO CORONADO, Portugal and LONDON, April 28 /PRNewswire/ -- - New Option for Treatment of Epilepsy Patients With Partial Onset Seizures Bial-Portela & CA, S.A., (S. Mamede do Coronado, Portugal, President & CEO Dr Luis Portela), and Eisai Europe Limited (London; Chairman & CEO Yutaka Tsuchiya), the European subsidiary of Eisai Co., Ltd. (Tokyo, President & CEO: Haruo Naito), today announced that the novel once daily anti-epileptic Zebinix(R)*...

2008-12-08 09:00:00

PORTO, Portugal, December 8 /PRNewswire/ -- - Data Highlight The Efficacy, Safety and Significant Improvement in Quality of Life and Depressive Symptoms With Zebinix(TM) (Eslicarbazepine Acetate) Positive data from three phase III studies presented today at the American Epilepsy Society (AES) Congress, Seattle, USA, show that Zebinix(TM)(1) (eslicarbazepine acetate), a novel once-daily anti-epileptic agent, significantly reduced the frequency of partial seizures and has the...

2008-12-06 18:30:00

SEATTLE, Dec. 6 /PRNewswire/ -- Phase III data on carisbamate, an investigational compound recently filed with the FDA for the adjunctive treatment of partial onset seizures (POS) in patients 16 years of age and older, was presented today during the poster sessions of the 32nd Annual Meeting of the American Epilepsy Society. Results from two identical placebo-controlled clinical trials investigating the efficacy, safety and tolerability of carisbamate as an adjunctive treatment for...